TaiGen in strategic agreement with Procter & Gamble
TaiGen Biotechnology has signed a strategic alliance with Procter & Gamble Pharmaceuticals (P&GP) to further the development and commercialisation of a novel non-fluorinated quinolone antibiotic, invented by P&GP.
TaiGen Biotechnology has signed a strategic alliance with Procter & Gamble Pharmaceuticals (P&GP) to further the development and commercialisation of a novel non-fluorinated quinolone antibiotic, invented by P&GP.
Under the terms of the agreement, TaiGen will be responsible for conducting Phase Ib and Phase II development of the compound. If Phase II results are positive P&G, in conjunction with TaiGen, may then seek a pharmaceutical partner for the Phase III development and subsequent commercialisation.
The agreement also entitles TaiGen to development and commercialisation rights within China, Taiwan, Korea and the ASEAN countries.